1. Scrip
  2. >>Business
  3. >>Earnings

Regeneron Follows REGEN-COV Revenue Success With Impressive PD-1 Data

Libtayo Showed Efficacy With Chemo In 1L NSCLC

 
• By Jessica Merrill

Regeneron reported $2.76bn in revenues from the sale of its COVID-19 antibody cocktail, and that Libtayo in combo with chemotherapy was effective in NSCLC.

Regeneron
Regeneron had a strong second quarter. • Source: Alamy

Regeneron Pharmaceuticals, Inc. reported stellar second quarter sales and earnings on 5 August with revenues up 163% to $5.14bn, powered by $2.76bn in revenues from REGEN-COV, the antibody cocktail for the treatment of COVID-19. That success should help support the company’s goals in oncology, where it has a wave of new bispecifics in the clinic and new data that will help its late-to-market PD-1 inhibitor Libtayo compete in the challenging lung cancer market.

Excluding REGEN-COV (casirivimab/imdevimab), the company reported solid 22% growth with key brands Eylea (aflibercept), Dupixent (dupilumab) and Libtayo (cemiplimab) delivering

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

More from Business

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.